BRKB

481.25

+0.09%↑

BRKA.US

721,729.2

+0.11%↑

JPM

292.71

+0.41%↑

V

303.86

-0.92%↓

MA

499.64

-1.08%↓

BRKB

481.25

+0.09%↑

BRKA.US

721,729.2

+0.11%↑

JPM

292.71

+0.41%↑

V

303.86

-0.92%↓

MA

499.64

-1.08%↓

BRKB

481.25

+0.09%↑

BRKA.US

721,729.2

+0.11%↑

JPM

292.71

+0.41%↑

V

303.86

-0.92%↓

MA

499.64

-1.08%↓

BRKB

481.25

+0.09%↑

BRKA.US

721,729.2

+0.11%↑

JPM

292.71

+0.41%↑

V

303.86

-0.92%↓

MA

499.64

-1.08%↓

BRKB

481.25

+0.09%↑

BRKA.US

721,729.2

+0.11%↑

JPM

292.71

+0.41%↑

V

303.86

-0.92%↓

MA

499.64

-1.08%↓

Search

Byline Bancorp Inc

Open

BrancheFinanzen

31.32 0.48

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

30.33

Max

31.38

Schlüsselkennzahlen

By Trading Economics

Einkommen

179M

217M

Verkäufe

-2.6M

160M

KGV

Branchendurchschnitt

10.571

54.048

EPS

0.83

Dividendenrendite

1.31

Gewinnspanne

135.435

Angestellte

1,018

EBITDA

7.1M

58M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+15.66% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.31%

4.84%

Nächstes Ergebnis

23. Apr. 2026

Nächste Dividendenausschüttung

19. Mai 2026

Nächstes Ex-Dividendendatum

5. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-8.3M

1.4B

Vorheriger Eröffnungskurs

30.84

Vorheriger Schlusskurs

31.32

Nachrichtenstimmung

By Acuity

41%

59%

125 / 441 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Byline Bancorp Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. März 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23. März 2026, 22:55 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23. März 2026, 21:51 UTC

Akquisitionen, Fusionen, Übernahmen

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23. März 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23. März 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23. März 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23. März 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23. März 2026, 22:42 UTC

Market Talk
Wichtige Nachrichtenereignisse

Global Equities Roundup: Market Talk

23. März 2026, 22:42 UTC

Market Talk
Wichtige Nachrichtenereignisse

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23. März 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23. März 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23. März 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23. März 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23. März 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23. März 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23. März 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23. März 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23. März 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23. März 2026, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23. März 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23. März 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23. März 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. März 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23. März 2026, 21:10 UTC

Wichtige Nachrichtenereignisse

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23. März 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23. März 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23. März 2026, 20:50 UTC

Market Talk
Ergebnisse
Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Byline Bancorp Inc Prognose

Kursziel

By TipRanks

15.66% Vorteil

12-Monats-Prognose

Durchschnitt 35 USD  15.66%

Hoch 37 USD

Tief 33 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Byline Bancorp Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

1

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

26 / 26.43Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

125 / 441 Ranking in Finanzen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Byline Bancorp Inc

Byline Bancorp, Inc. operates as the bank holding company for Byline Bank that provides various banking products and services for small and medium sized businesses, commercial real estate and financial sponsors, and consumers in the United States. It offers various retail deposit products, including non-interest-bearing accounts, money market demand accounts, savings accounts, interest-bearing checking accounts, and time deposits; ATM and debit cards; and online, mobile, and text banking services, as well as commercial deposits. The company also provides term loans, revolving lines of credit, and construction financing services; senior secured financing solutions to private equity backed lower middle market companies; small business administration and united states department of agriculture loans; and treasury management products and services. In addition, it offers financing solutions for equipment vendors and their end users; syndication services; and investment, trust, and wealth management services that include fiduciary and executor services, financial planning solutions, investment advisory services, and private banking services for foundations and endowments, and high net worth individuals. The company was formerly known as Metropolitan Bank Group, Inc. and changed its name to Byline Bancorp, Inc. in 2015. Byline Bancorp, Inc. was founded in 1914 and is headquartered in Chicago, Illinois.
help-icon Live chat